Navigation Links
Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization
Date:6/27/2011

MENLO PARK, Calif., June 27, 2011 /PRNewswire/ -- Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that the U.S. Patent and Trademark Office (USPTO) issued patent number 7,963,906 covering three predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn's early embryo viability assessment (Eeva™) System.

"This patent is the first to issue from a portfolio of patents filed related to our Eeva System in the United States, Europe and other countries," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "We believe the value of our technology lies in the unique ability of our proprietary parameters to evaluate and predict, by day 2, the embryos that will continue development to blastocyst stage, which happens on day 5 of human development. By providing novel clinical data to IVF clinicians early, this non-invasive clinical tool has the potential to improve clinical pregnancy rates for IVF patients."

The Eeva System uses proprietary software to measure the three predictive parameters from time lapse video images of the embryos developing in a standard incubator and identify  on day 2 which embryos are most likely to continue development into blastocysts (day 5). Blastocyst formation is a critical milestone in human embryo development and provides objective criteria for selecting which embryo(s) to transfer. Use of the Eeva System is investigational, and the Eeva System has not been cleared by the U.S. Food and Drug Administration for commercial sale.

Auxogyn's proprietary non-invasive Eeva System is based on research of early human embryo development conducted at Stanford University and published in the October 2010 issue of Nature Biotechnology. The U.S. patent 7,963,906 was issued to Stanford University. Auxogyn has an exclusive license from Stanford University with worldwide rights to develop products based on intellectual property that includes this patent.

About Auxogyn

Auxogyn is a privately held medical technology company focused on advancing women's reproductive health by applying its novel scientific and clinical knowledge of early human developmental biology to the field of assisted reproduction and in vitro fertilization procedures. Auxogyn is funded by the leading life science venture firms Kleiner Perkins Caufield & Byers, TPG Biotechnology and Merck Serono Ventures. For more information regarding Auxogyn please visit www.auxogyn.com.


'/>"/>
SOURCE Auxogyn, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 ... 2017 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital ... environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new ... robot that uses UVC light energy to kill deadly pathogens such as C. diff ... Tru-D SmartUVC ... Tru-D in action in a ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple Rehab Watch Hill , ... received training and certification in Closed Pulse Irrigation™ (CPI) for wound care. ... from the Centers for Medicare and Medicaid Services, to have a CPI machine that ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a ... B17 bomber named Edward Koontz. “To Walk Away” is the creation of published author, ... published over two hundred manuscripts in chemistry and religion, as well as four novels. ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty and Pleasures ... the struggles faced while hoping for a better life. “Without Love’s Beauty and ... Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost 20 years ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
(Date:8/22/2017)... Overland Park, KS (PRWEB) , ... August 22, 2017 , ... ... sellers of products to fight Fatigue . , As the stress of modern ... to keep up the pace. Constant use of artificial stimulants can trap people in ...
Breaking Medicine News(10 mins):